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p53 mediates cell cycle arrest or apoptosis in response to DNA damage. Its activity is subject to a tight regulation involving a
multitude of post-translational modifications. The plethora of functional protein interactions of p53 at present precludes a clear
understanding of regulatory principles in the p53 signaling network. To circumvent this complexity, we studied here the minimal
requirements for functionally relevant p53 post-translational modifications by expressing human p53 together with its best
characterized modifier Mdm2 in budding yeast. We find that expression of the human p53-Mdm2 module in yeast is sufficient to
faithfully recapitulate key aspects of p53 regulation in higher eukaryotes, such as Mdm2-dependent targeting of p53 for
degradation, sumoylation at lysine 386 and further regulation of this process by p14
ARF. Interestingly, sumoylation is necessary for
the recruitment ofp53-Mdm2 complexes to yeast nuclear bodies morphologically akin to human PML bodies. Theseresults suggest
a novel role for Mdm2 as well as for p53 sumoylation in the recruitment of p53 to nuclear bodies. The reductionist yeast model that
was established and validated in this study will now allow to incrementally study simplified parts of the intricate p53 network, thus
helping elucidate the core mechanisms of p53 regulation as well as test novel strategies to counteract p53 malfunctions.
Citation: Di Ventura B, Funaya C, Antony C, Knop M, Serrano L (2008) Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in
Yeast. PLoS ONE 3(1): e1507. doi:10.1371/journal.pone.0001507
INTRODUCTION
Acting as a sensor of DNA damage, p53 dictates life or death
depending on the ability of the cell to cope with the damage and
repair it. It is therefore subject to a tight regulation achieved by a
complex protein network [1]. p53, an evolutionarily conserved
protein from worm to humans, is a sequence-specific DNA-
binding transcription factor. Under normal growth conditions,
p53 is kept latent in various ways, e.g. by keeping it in the
cytoplasm, by targeting it for proteasomal degradation, or by
inhibiting binding to its DNA target sites [2]. When exposed to
DNA-damage, the cell invokes p53 to take action. p53 is quickly
stabilized and its transcriptional activity is strongly enhanced as a
result of the nuclear accumulation of the protein and modifications
within both its N- and C-termini [2]. Although the rise in p53
protein levels is partially due to a higher translational rate of p53
mRNA, the major players in p53 stabilization are post-
translational modifications, which prevent the association of p53
with its negative regulators [3]. Mdm2 is the best-characterized
p53 negative regulator to date. Mdm2 N-terminus binds the N-
terminal transactivation domain of p53 [4]. This binding inhibits
p53 transcriptional activity independently of the ubiquitin ligase
function of Mdm2, which resides in the C-terminal RING-finger
domain [5]. In addition to mono- and poly-ubiquitylation, Mdm2
is involved in the neddylation and sumoylation of p53 [6,7]. While
neddylation has been reported to inhibit p53 transcriptional
activity [7], the precise role of sumoylation on the activity and
localization of p53 is still unclear, although p53 sumoylation seems
to be related to the association of the protein with nuclear
organelles such as the nucleolus [6,8] and PML bodies [8].
Given the high complexity of the p53 network, distinguishing
between the contributions of each individual protein to p53 regula-
tion is a difficult task. We aimed at studying p53-Mdm2 functional
interplay in the absence of the other regulators in the p53 network,
while at the same time maintaining important eukaryotic cell
characteristics. We have chosen to use the budding yeast Saccharomyces
cerevisiae since p53 and the majority of its regulators are foreign to its
genome, therefore this organism provides us with the perfect tool to
study p53-Mdm2 interaction ‘‘in isolation’’ but at the same time in a
cellular context. In the past it has been shown that p53 can bind to its
consensus sequences and recruit the yeast transcription machinery to
start expression of downstream genes [9–11], a process that can be
inhibited by co-expressionwithMdm2[4]. Here weshowthat Mdm2
can interact with endogenous yeast pathways to ubiquitylate and
sumoylate p53. Ubiquitylation leads to p53 degradation, while
sumoylation is essential for the localization of p53-Mdm2 complexes
to yeast nuclear bodies. These domains are morphologically akin to
human PML bodies and human PML proteins are also found to
relocate there. We conclude that yeast can be used as a model
organism to study p53 post-translational modifications and their
regulatory effects on p53 function and localization.
MATERIALS AND METHODS
Yeast strains, growth media and growth conditions
The yeast strain used in this study is ESM356-1 (S288c genetic
yeast background), with genotype Mata ura3-53 leu2D1 his3D200
trp1D63. Cultures were grown at 30uC in synthetic complete (SC)
media with 2% raffinose, lacking one or more amino acids for
maintenance of plasmids. Basic yeast techniques were as described
in [12].
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The human p53 wild type cDNA was amplified by PCR from the
plasmid pRS314-SN (kind gift of Prof. Bert Vogelstein) and cloned
into the centromeric plasmid p413-GALS, containing the HIS3
marker, the GALS promoter and the CYC1 terminator [13]. For
microscopyanalysis,thep53cDNAintopRS314-SNwassubstituted
with the fusion p53-eCFP generated by PCR as in [14]. The human
mdm2 wild type cDNA was amplified by PCR from pCDNA3.1-
Mdm2 (kind gift of Dr. Cayetano Gonzales) and cloned into the
centromeric plasmids p416-TEF/GALS containing the URA3
marker, either the TEF or GALS promoter and the CYC1
terminator. For microscopy analysis, the mdm2 cDNA was
substituted with the fusion mdm2-eYFP generated by PCR as in
[14]. The human p14
ARF cDNA was digested out of the plasmid
pLPC (kind gift of Dr. Cayetano Gonzales) and cloned into the
vector p414-TEF, containing the TRP1 marker, the TEF promoter
and the CYC1 terminator. The ECFP and EYFP genes were
amplified from the plasmids pECFP-N1 and pEYFP-N1 respectively
(Clontech). The human mdm2 cDNA lacking the RING finger
domain was generated inserting a STOP codon in place of residue
440, using the Quickchange site-directed mutagenesis (Stratagene).
All p53 and Mdm2 mutants used in this study were obtained by
Quickchange site-directed mutagenesis (Stratagene). All constructs
used in this study have been fully sequenced.
Analysis of protein turnover in yeast cells
Cultures were cultivated at 30uC on a shaker at 230 rpm for
14 hours and diluted in the morning to an OD600 of 0.1–0.2. Two
hours later (with cells typically at OD600 of 0.3), galactose was
added to a final concentration of 0.5%. Cells were incubated for
1.5 hours before glucose was added to a final concentration of 3%
to stop gene expression. The first sample (sample ‘0’) was collected
half an hour after addition of glucose to the medium. The
remaining samples were collected two, four and six hours
afterwards. Crude cell extracts for western blotting were generated
as described (Knop et al. 1999). Equal volumes of samples were
analysed by SDS-PAGE followed by Western Blotting. p53 was
detected using the monoclonal antibody Pab 1801 (Santa Cruz
biotech). Mdm2 was detected using the monoclonal antibody
SMP14 (Santa Cruz biotech). PGK was detected using the
monoclonal antibody 22C5 (Molecular Probes). The secondary
antibody was peroxidase-conjugated donkey anti-mouse (Jackson
Immuno Reasearch Laboratories). Protein levels were quantified
using Adobe Photoshop calculating ratios to the loading control
(PGK).
Purification of 6xHIS-tagged proteins for detecting
SUMO-conjugated p53
1l yeast culture was grown and induced (at OD,1.5) for 2.5 hours
with galactose at a final concentration of 2% and then lysed
mechanically using glass beads, under denaturing conditions.
Lysates were then purified on Ni
+-NTA sepharose beads (GE
Healthcare). Elution was done with 200 mM imidazole. Detection
of sumoylated proteins was done using a rabbit polyclonal
antibody anti-Smt3 [15]. Detection of p14
ARF was done using
the rabbit polyclonal antibody ab3642 (abcam).
Microscopic techniques
For live cells imaging, cells were adhered with Poly-lysine on small
glass bottom Petri dishes (MaTek). All live cell experiments were
performed at RT. Live cell imaging was performed on an imaging
system(DeltaVisionSpectris;Applied Precision)equipped withfilters
(ChromaTechnology Corp.) to detect CFP,YFP and red fluorescent
proteins, a 100x NA 1.4 oil immersion objective (plan Apo, IX70;
Olympus), softWorRx software (Applied Precision), and a Cool-
SNAP HQ camera. ImageJ software was used to mount the images
and to produce merged colour images. The width of the stacks taken
was always such that it encompassed at least the thickness of the cell
nucleus (spacing 0.5 mm). Maximum projections of the fluorescence
images were generated and coloured using ImageJ software. For the
time-lapse microscopy, p53 localization over time was not imaged to
avoid bleaching of the signals. Only Mdm2 localization was followed
over time. p53 expression in each cell was verified taking stacks
before and after the time-lapse. For immunofluorescence microsco-
py, cells were fixed with 3.7% formaldehyde for 60 min in the
medium (adjusted to 0.1 M KxHyPO4, pH 6.5). Digestion of cells
using Zymolyase 100T and immunolabeling was performed as
described in [16]. For triple labeling, primary antibodies (p53: goat
polyclonal N-19 (Santa Cruz biotech); Mdm2: rabbit polyclonal H-
221(SantaCruzbiotech);NOP1:mousemonoclonal,kindgiftofDr.
Ed Hurt) were detected using Cy2-, Cy3-, and Cy5-labeled donkey
antibodies (Jackson Immuno Reasearch Laboratories).
Electron microscopy
Yeast cells were cryofixed in an EMPACT-2 high-pressure freezer
(Leica Microsystems, Vienna, Austria) and further processed for
freeze substitution. The freeze substitution solution was 0.2 %
Glutaraldehyde, 0.1 % Uranyl acetate and 1 % water in acetone.
The samples were then embedded in lowicryl HM20 (Polysciences,
Warrington, PA, USA) in a freeze substitution device (EM-AFS
Leica Microsystems, Vienna, Austria). Ultrathin sections were
prepared using a Reichert UltracutE microtome (Leica Micro-
systems, Vienna, Austria).Non-specific bindingsites wereblockedby
incubating sections in blocking buffer (0.1 % fish skin gelatin, 1.5 %
BSA in PBS) for 15 min. Sections were incubated with mouse
primaryantibodies(eitheranti-p53 Pab 1801oranti-Mdm2SMP14,
concentration 1:2) for 30 min before extensive rinsing and further
incubation with a rabbit anti-mouse (DAKO cytomation, concen-
tration 1:150) linker antibody followed by final Protein A-Gold
(10 nm, CMC university medical center Utrecht) conjugates for
20 min. Sections were fixed in 1% glutaraldehyde in PBS for 5 min,
rinsedwithwaterandcontrastedwithuranylacetateandleadcitrate.
Sections were then viewed and pictures were acquired in a CM120
biotwin electron microscope (FEI, Eindoven, The Netherlands)
operating at 100 kV. Digital acquisitions were made with a Keen
View CCD camera (Soft Imaging System, Muenster, Germany).
RESULTS
Yeast has been first used to show the ability of Mdm2 to bind to and
conceal the p53 transactivation domain [4]. It has been then used
to study p53 transcriptional activity [9], as well as the requirements
for p53 degradation in human cells by E6-E6AP [21]. These results
proved that yeast expressing human p53 and Mdm2 can grow, that
p53 and Mdm2 can interact in yeast and that p53 can bind to
consensus sequences, recruit the yeast transcription machinery and
induce expression of downstream genes, as we also observed with
Mdm2 (Figure S1). Mdm2-dependent p53 post-translational
modifications, such as ubiquitylation and sumoylation, and
subsequent p53 degradation have not yet been shown to occur in
this organism. The conservation of the ubiquitin–and ubiquitin-
like–pathway from yeast to humans gives us good reasons to believe
that the human E3 ubiquitin ligase Mdm2 could interact with the
yeast ortologue(s) of the human E2 conjugating enzyme(s) that
allow the ubiquitylation reaction to take place [22]. Indeed, the
high sequence similarity of the interested proteins suggests the
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therefore devised an experimental set-up to study Mdm2-
dependent p53 post-translational modifications in yeast.
p53 is stable in yeast and localizes to the nucleus
We expressed p53 under the control of the inducible GAL1
promoter. Expression of the gene was triggered by the addition of
galactose to the medium and repressed adding glucose to the
same medium. The pool of protein made in the time window
between addition of galactose and glucose was then followed for
a period of six hours. p53 showed little degradation in yeast
(around 30% in six hours) under these conditions (Figures 1A and
1B).
We also performed in vivo microscopy on cells expressing the
fusion protein p53-ECFP, which has been previously shown to be
functional and to retain a wild type localization in human cells
[14]. p53 accumulated in the yeast nucleus and was also present in
the cytoplasm (Figure 1C), which corresponds to the reported
localization in human cells. In addition, in budding cells, the
protein was also found at the bud neck and sometimes unbudded
cells showed a ring-like localization at the plasma membrane,
which might correspond to sites of previous cytokinesis
(Figure 1D).
Mdm2 is degraded in yeast and localizes to nuclear
speckles
We studied Mdm2 degradation following the same method used
for p53. We observed that, unlike p53, Mdm2 was rapidly
degraded in yeast (Figures 1E and 1F) (around 60% in two
hours). Mutating histidine 452 in the RING finger domain of
Mdm2 was not sufficient to abolish its E3 ligase activity in yeast
(data not shown). When a truncated protein missing the C-
terminal RING finger domain (Mdm2NORING) was used
instead of the wild type protein, we found that degradation was
strongly impaired (Figures 1E and 1F) (around 25% in six hours).
Since the RING finger domain has been shown to be responsible
for Mdm2 self-ubiquitylation in human cells (Fang et al. 2000),
our data suggest that Mdm2 is degraded in yeast due to self-
ubiquitylation.
The fusion protein Mdm2-EYFP [14] was detected in the nucleus
of yeast living cells (Figure 1 G), often within speckles (Figure 1 F).
Figure 1. Stability and localization of the human p53 and Mdm2
proteins in yeast. (A) Total yeast cell extracts from exponentially
growing cells were immunoblotted for p53 over time. 3-phosphoglyc-
erate kinase (PGK) was used as loading control. (B) Quantifications of
p53 protein levels are shown. Data represent the mean 6 standard
error (SE), for n=3 independent experiments. (C,D) Maximum
projections from fluorescence image stacks of live yeast cells expressing
p53-ECFP were obtained with a DeltaVision workstation. Bar, 2 mm.
E,F,G,H. Same as in (A,B,C,D) but for Mdm2.
doi:10.1371/journal.pone.0001507.g001
Figure 2. Mdm2 ubiquitylates p53 in yeast leading to p53 degradation. (A) Total yeast cell extracts from exponentially growing cells were
immunoblotted for the indicated proteins over time. 3-phosphoglycerate kinase (PGK) was used as loading control. (B) Quantifications of protein
levels are shown. Data represent the mean 6 standard error (SE), for n=3independent experiments. (C,D) as in (A,B) but for p53W23S. (E,F) as in (A,B)
but for p53Lys2Arg.
doi:10.1371/journal.pone.0001507.g002
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We then co-expressed p53 and Mdm2. While the mdm2 cDNA
was under the control of a constitutive promoter (TEF), the p53
cDNA was under the control of the inducible GAL1 promoter. In
this way, Mdm2 proteins were constantly produced, while only a
pool of p53 proteins was produced which we followed over time.
p53 was degraded in the presence of Mdm2 (Figures 2A and 2B).
When a truncated Mdm2 protein (Mdm2NORING) missing the
Figure 3. p53 and Mdm2 co-localize in yeast cells. (A,B) Maximum projections from fluorescence image stacks of live yeast cells expressing the
indicated fusion proteins were obtained with a DeltaVision workstation. Bar, 2 mm. (C) Indirect immunofluorescence of fixed yeast cells stained for
p53-Mdm2 bodies (primary antibody: goat polyclonal N-19 anti-p53; secondary antibody: Cy2-labeled donkey anti-goat; showed in green), Nop1
(primary antibody: mouse monoclonal; secondary antibody: Cy5-labeled donkey anti-mouse; showed in red) and chromatin (detected with Ho ¨echst,
showed in blue). (D) Time-lapse microscopy on yeast cells expressing p53 and Mdm2 obtained recording image stacks and then performing
maximum projections of live yeast cells at the indicated times. Galactose was added directly into the Petri dish to trigger p53 expression and time-
lapse started shortly after. Mdm2 is shown in red and the phase-contrast image of the cells in blue.
doi:10.1371/journal.pone.0001507.g003
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ubiquitin ligase activity in human cells (Fang et al. 2000)–was used
instead of wild type Mdm2, p53 showed little degradation
(Figures 2A and 2B), as in the absence of Mdm2 (Figures 1A
and 1B). Similarly, degradation was severely reduced when we co-
expressed Mdm2 with either a mutant p53 with impaired binding
to it (p53W23S) (17) (Figures 2C and 2D) or with a mutant p53 in
which the C-terminal lysines at positions 372, 373, 382 and 383
were replaced by arginines (p53Lys2Arg), to prevent ubiquityla-
tion keeping the overall charge of the protein unchanged [18]
(Figures 2E and 2F). Taken together, these data suggest that
Mdm2 ubiquitylates p53 targeting it for degradation in yeast.
p53 and Mdm2 co-localize to PML-like nuclear
bodies in yeast
Notably, co-expressing p53-ECFP and Mdm2-EYFP revealed that
the two proteins co-localized to one or more nuclear dots, to which
we will refer as p53-Mdm2 bodies (Figure 3A). This co-localization
was lost when the mutant p53W23S was used in place of wild type
Figure 4. p53-Mdm2 complexes localize to yeast nuclear bodies morphologically akin to human PML bodies. Immunogold labeling against p53
(A,D,E) or Mdm2 (C,F) of thin sections of yeast cells expressing the indicated proteins. Total number of cells analyzed for each case: 10. (B)
Magnification of the p53-Mdm2 body (arrowhead) in the cell in panel A.
doi:10.1371/journal.pone.0001507.g004
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required for this localization. These structures were visible also
when performing indirect immunofluorescence (Figure 3C), there-
fore they were not triggered by fusing the proteins to the fluorescent
tags. Using an antibody againstthe yeast nucleolar protein Nop1, we
analyzed the localization of the p53-Mdm2 bodies in respect to the
nucleolus. We did not find substantial overlap between the signals
corresponding respectively to the anti-Nop1 and the anti-p53/
Mdm2 antibodies, therefore we concluded that p53-Mdm2 bodies
did not reside in the nucleolus (Figure 3C). The p53-Mdm2 bodies
were most often found in regions of the nucleus adjacent to the
nucleolus(Figures3C and4A,C,D).Time-lapse microscopy revealed
that p53-Mdm2 co-localization is stable over time (Figure 3D). Soon
after its expression, p53 is found in the discrete loci where Mdm2 is
localized (data not shown), but the p53-Mdm2complexes then move
towards a bigger structure (Figure 3D). We next investigated the
morphology andlocalization within thecellof the p53-Mdm2 bodies
using immunoelectron microscopy (Figure 4). The immunostaining
detected areas containing electron dense fibrillar spheroids with a
doughnut-like shape (13 out of 16 cells analyzed, Figures 4A–D),
reminiscentof humanPMLbodies[19].Cells expressing onlyp53or
only Mdm2showed a diffusepattern of the gold particles (Figures 4E
and 4F), therefore confirming that the formation of the bodies
required both p53 and Mdm2.
PML can re-locate to the p53-Mdm2 bodies in yeast
Given the morphological similarity between the p53-Mdm2 bodies
in yeast and human PML bodies, we next investigated the
localization of human PML, alone or together with p53 and/or
Mdm2 in yeast cells. PML localized to the nucleus, mostly to one or
more discrete loci (Figure 5A). Upon co-expression with PML, p53
could still accumulate in the nucleus (Figure S2) and co-localized
with PML in 50% of the cells to relatively large, but still discrete
subregions of the nucleus (Figures 5B and 5E). However, unlike
when it was co-expressed with Mdm2, p53 was still detectable in
the nucleoplasm and the cytoplasm (compare Figures 3A and 5B).
When co-expressed, Mdm2 and PML co-localized in 40% of the
cells, indicating that the two proteins could interact but also
retained separate localizations (Figures 5C and 5E). When p53,
Mdm2 and PML were co-expressed, we observed the typical
localization of p53-Mdm2 complexes to the bodies, into which
PML could relocate in 73% of the cases (Figures 5D and 5E).
Mdm2 sumoylates p53 in yeast alone or
synergistically with p14
ARF
We affinity precipitated p53 from denaturing extracts of cells
expressing the protein either alone or with Mdm2. p53 precipitates
were then analyzed for sumoylation using an anti-Smt3 antibody,
which is directed against the yeast SUMO protein (Figure 6A).
Only in cells co-expressing wild type p53 and Mdm2 we could
detect a band which was simultaneously recognized by the anti-
p53 and the anti-Smt3 antibodies, and which ran at a size
consistent with the conjugation of a single SUMO protein to p53
(Figure 6A, asterisks). This slower-migrating form of p53 could
also be detected on western blot on crude lysates, provided high
amount of proteins was loaded on the gel and the film was exposed
for longer times (Figures 6B and S3).
In human cells, lysine 386 is known to be the major site for p53
sumoylation since, when this residue is mutated to arginine, p53
sumoylation is abolished (Gostissa et al. 1999). When we used this
mutant p53K386R in yeast in place of wild type p53 no SUMO
conjugation was detectable on p53 (Figures 6A,B and S3). Given
that binding of p53 to Mdm2 is required for the modification to
take place, sumoylation was also abolished when we co-expressed
Mdm2 with a mutant p53 which is impaired in binding to Mdm2
(p53W23S, see above) (Figures 6B and S3).
Since p14
ARF has been shown to enhance Mdm2-dependent
p53 sumoylation in human cells (6), we co-expressed p53, Mdm2
and p14
ARF in yeast cells. We found that indeed p14
ARF led to
enhanced p53 sumoylation (Figure 6C).
p53 sumoylation and Mdm2 are necessary for p53-
Mdm2 co-localization to the nuclear bodies
Sumoylation is known to affect the subcellular localization of
proteins, often correlating with their affiliation with nuclear bodies
[8,20]. Consequently, we thought that SUMO conjugation to p53
might be related to the localization of p53-Mdm2 complexes to
nuclear bodies in yeast. We found that, when expressed alone,
p53K386R could accumulate in the nucleus like wild type p53
(Figure 6D), but indeed inhibiting sumoylation disrupted p53 and
Mdm2 co-localization to the nuclear domain (Figure 6E). In light
of this result we can also interpret the failed co-localization of
p53W23S with Mdm2 (Figure 3B) since binding of p53 to Mdm2
is necessary for the sumoylation to take place (see above and
Figures 5B and S3). When SUMO was fused to the non-
sumoylatable p53 mutant p53K386R (SUMOp53K386R-ECFP)
we could rescue the formation of the bodies, provided Mdm2 was
present in the same cells (Figure 6F). These data suggest that the
interaction with Mdm2 is required for the localization to the
bodies and that SUMO has a binding rather than a structural role
Figure 5. The human PML protein can relocate to the p53-Mdm2
bodies in yeast. (A,B,C,D) Maximum projections from fluorescence
image stacks of live yeast cells expressing the indicated fusion proteins
were obtained with a DeltaVision workstation. Bar, 2 mm. (E) Table
showing the percentage of cells in which the indicated proteins co-
localize. Percentages were calculated from more than 100 cells each.
doi:10.1371/journal.pone.0001507.g005
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PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1507Figure 6. Mdm2 sumoylates p53 in yeast on lysine 386 and sumoylation is required for p53-Mdm2 complexes recruitment to yeast nuclear
bodies. (A) His-tagged proteins were purified from cell extracts and analyzed by immunoblotting using anti-p53 and anti-Smt3 antibodies. (B,C)
Sumoylated p53 (asterisks) as detected by immunoblotting on crude yeast lysates. An irrelevant lane was cut off as indicated by a space. PGK
immunoblotting served as loading control. (D–G) Maximum projections from fluorescence image stacks of live yeast cells expressing the indicated
fusion proteins were obtained with a DeltaVision workstation. Bar, 2 mm.
doi:10.1371/journal.pone.0001507.g006
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bodies with Mdm2 (Figure 6G).
DISCUSSION
The aim of this study was to reconstitute a minimal part of the
complex p53 network in yeast to study the mechanisms of p53
regulation by MDM2 in isolation from their natural genomic and
proteomic environments. By expressing human p53 and Mdm2 in
normally growing yeast cells we could reproduce Mdm2-
dependent p53 degradation, which is the key outcome of Mdm2
negative regulation on p53. Even if we did not manage to directly
detect ubiquitins attached to p53, our data strongly support the
idea that Mdm2 could interact with the yeast enzymes in the
ubiquitylation pathway to ubiquitylate p53 and target it to
proteasomal degradation.
Recently, the central role of Mdm2 in keeping p53 levels low
under normal growth conditions has been questioned, due to the
discovery of several other E3 ubiquitin ligases for p53, some of
which are not, unlike Mdm2, p53 transcriptional targets [23]. Our
findings suggest that Mdm2 is a key negative regulator for p53
even in normal growth conditions.
Besidesubiquitylation,Mdm2hasalsobeenreportedtosumoylate
and neddylate p53 [6,7], but its precise role in these processes is less
well understood. Our findings here indicate that Mdm2-mediated
p53 sumoylation is an important event that takes place in yeast on
the same lysine residue targeted in human cells. Moreover, the
mechanisms of sumoylation could be reconstituted in yeast since,
when the human protein p14
ARF was co-expressed with p53 and
Mdm2, we observed an increase in p53 sumoylation levels in
accordance with what was reported by Chen and colleagues [6].
Taken together, these results suggest that p53 ubiquitylation
and sumoylation by Mdm2 and its increased activation by p14
ARF
do not require additional components.
p53 degradation was not detectable when samples were
collected from cells close to the stationary phase (data not shown).
An intriguing possibility is that the enzymes in the ubiquitylation
pathway needed for p53 degradation are somehow inactive at that
stage. Interestingly, Mdm2 levels also decreased (Figure 2A)
despite its being under a constitutive promoter. This suggests that
the ubiquitylation reaction towards p53 somehow enhances
Mdm2 self-ubiquitylation, and in fact when the protein was co-
expressed with a mutant p53 which cannot bind to it (p53W23S),
Mdm2 levels accumulated over time (Figure 2C).
Unexpectedly, p53-Mdm2 complexes localize to nuclear bodies in
yeast, which exhibit a doughnut-like shape morphologically akin to
human PML bodies [19]. Human PML proteins expressed in yeast
can relocate to these domains. Beyond the morphological similarity
between the PML and p53-Mdm2 bodies, we find that sumoylation
ofp53 isessentialfor thislocalization,justlikesumoylationofPML is
essential for the PML bodies’ formation [24]. When co-expressed
with Mdm2, the non-sumoylatable p53K386R can no longer
localize to nuclear bodies and fails to accumulate in the nucleus
(Figures 6D and 6E). We suggest that sumoylation might affect the
equilibrium between p53 nuclear import and export helping to
retain p53 into the nucleus. Sumoylation is also needed to localize
p53 to the nuclear bodies, therefore, when sumoylation is impaired,
p53 export is less counterbalanced and we see an accumulation of
the protein in the cytoplasm. Binding to Mdm2 also helps retaining
p53 into the nucleus since, when the binding is abolished, p53 also
accumulates in the cytoplasm (Figure 3B). p53-Mdm2 co-localiza-
tion to the PML-like bodies is recovered when SUMO is fused to
p53K386R N-terminus, indicating a binding rather than a structural
role for SUMO in this process. In human cells, sumoylation does not
seem to be necessary for p53 recruitment into PML bodies, since
p53K386R is also found there [25]. The discrepancy between what
is observed in yeast and human cells could lie in the existence of so
far unidentified human proteins that can relocate the non-
sumoylatable p53 to PML bodies (beyond PML itself) and that are
absent in yeast. Since PML has been shown to be necessary for the
formation of human PML bodies [24], our data hint at the existence
of a yeast protein(s) with no straightforward sequence similarity to
PML but with likely structural and/or functional homology to it.
Finally, p53 recruitment to PML bodies has been shown to take
place via direct binding to PML [25]. Our findings reveal that only
p53-Mdm2 complexes are localized to the bodies, while p53 alone,
co-expressed with PML, co-localizes with PML but is also found in
the cytoplasm and the nucleoplasm (Figure 5B). We therefore
speculate an active role for Mdm2 in the recruitment of p53 in
human PML bodies.
Our study of the human p53-Mdm2 module in yeast gives rise
to a whole new set of issues which might be important for
understanding p53 biology in higher eukaryotes, for instance
Mdm2 localization to nuclear speckles similar to that of telomere-
binding proteins such as RAP1 (Laroche et al. 2000), p53
localization to the septin ring, Mdm2 ability to recruit sumoylated
p53 to yeast nuclear bodies which resemble human PML bodies.
Importantly, we have now set the basis for further reconstruct the
p53-Mdm2 network in yeast. This should allow dissecting the
network and studying its dynamical aspects such as the ability of
the p53-Mdm2 negative feedback loop to generate oscillations.
SUPPORTING INFORMATION
Figure S1 p53-dependent Mdm2 expression in yeast cells. Cells
carrying a plasmid with the p53 cDNA under the GAL promoter
and a plasmid with the Mdm2 cDNA under a p53-responsive
promoter were grown up to exponential growth phase. Induction
of p53 expression was done with 0.5% final concentration of
galactose (corresponding to time 0 min). Glucose was not added to
stop induction.
Found at: doi:10.1371/journal.pone.0001507.s001 (0.62 MB TIF)
Figure S2 Co-expression with PML does not inhibit accumu-
lation of p53 into the nucleus. (A,B,C) Maximum projections from
fluorescence image stacks of live yeast cells expressing the
indicated fusion proteins were obtained with a DeltaVision
workstation. Bar, 2 mm. (A) Same as in Figure 1C.
Found at: doi:10.1371/journal.pone.0001507.s002 (3.79 MB TIF)
Figure S3 Mdm2 sumoylates p53 in yeast on lysine 386.
Sumoylated p53 (asterisks) as detected by immunoblotting on
crude yeast lysates using only anti-p53 antibody. The samples are
the same as those shown in Figure 6B. An irrelevant lane was cut
off as indicated by a space. PGK immunoblotting served as
loading control.
Found at: doi:10.1371/journal.pone.0001507.s003 (0.34 MB TIF)
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